The first in vivo multiparametric comparison of different radiation exposure biomarkers in human blood
The first in vivo multiparametric comparison of different radiation exposure biomarkers in human blood
Ales Tichy 0 1
Sylwia Kabacik 1
Grainne O'Brien 1
Jaroslav Pejchal 1 2
Zuzana Sinkorova 0 1
Adela Kmochova 0 1
Igor Sirak 1
Andrea Malkova 1
Caterina Gomila Beltran 1
Juan Ramon Gonzalez 1
Jakub Grepl 0 1
Matthaeus Majewski 1
Elizabeth Ainsbury 1
Lenka Zarybnicka 0 1
Jana Vachelova 1
Alzbeta Zavrelova 1
Marie Davidkova 1
Marketa Markova Stastna 1
Michael Abend 1
Eileen Pernot 1
Elisabeth Cardis 1
Christophe Badie 1
0 Department of Radiobiology, Faculty of Military Health Sciences, Hradec KraÂ lov eÂ, University of Defence in Brno , Hradec Kr aÂloveÂ , Czech Republic , 2 Biomedical Research Centre, University Hospital , Hradec Kr aÂloveÂ , Czech Republic , 3 Cancer Mechanisms and Biomarkers group, Radiation Effects Department, Centre for Radiation, Chemical and Environmental Hazards, Public Health of England , Didcot , United Kingdom
1 Editor: Gayle E. Woloschak, Northwestern University Feinberg School of Medicine , UNITED STATES
2 Department of Toxicology, Faculty of Military Health Sciences, Hradec KraÂ loveÂ , University of Defence in Brno, Czech Republic, 5 Department of Oncology and Radiotherapy and 4th Department of Internal Medicine - Hematology, University Hospital , Hradec KraÂ lov eÂ , Czech Republic , 6 Department of Hygiene and Preventive Medicine, Faculty of Medicine in Hradec KraÂ loveÂ , Charles University in Prague , Hradec Kr aÂloveÂ , Czech Republic , 7 Institute for Global Health , Barcelona , Spain , 8 Bundeswehr Institute of Radiobiology , Munich, Germany , 9 Department of Radiation Dosimetry, Nuclear Physics Institute of the Czech Academy of Sciences , Prague , Czech Republic , 10 Institute for Hematology and Blood Transfusion, Hospital Na Bulovce , Prague , Czech Republic
The increasing risk of acute large-scale radiological/nuclear exposures of population underlines the necessity of developing new, rapid and high throughput biodosimetric tools for estimation of received dose and initial triage. We aimed to compare the induction and persistence of different radiation exposure biomarkers in human peripheral blood in vivo. Blood samples of patients with indicated radiotherapy (RT) undergoing partial body irradiation (PBI) were obtained soon before the first treatment and then after 24 h, 48 h, and 5 weeks; i.e. after 1, 2, and 25 fractionated RT procedures. We collected circulating peripheral blood from ten patients with tumor of endometrium (1.8 Gy per fraction) and eight patients with tumor of head and neck (2.0±2.121 Gy per fraction). Incidence of dicentrics and micronuclei was monitored as well as determination of apoptosis and the transcription level of selected radiation-responsive genes. Since mitochondrial DNA (mtDNA) has been reported to be a potential indicator of radiation damage in vitro, we also assessed mtDNA content and deletions by novel multiplex quantitative PCR. Cytogenetic data confirmed linear dosedependent increase in dicentrics (p < 0.01) and micronuclei (p < 0.001) in peripheral blood mononuclear cells after PBI. Significant up-regulations of five previously identified transcrip-
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by the National
Institutes of Health (Centre for Minimally Invasive
radiation Biodosimetry, sub-award no:
GC00690034) (EC), Ministry of Defence of the Czech Republic
(long-term organization development plan Medical
Aspects of Weapons of Mass Destruction of the
Faculty of Military Health Sciences, University of
Defence), Ministry of Interior Affairs of the Czech
tional biomarkers of radiation exposure (PHPT1, CCNG1, CDKN1A, GADD45, and SESN1)
were also found (p < 0.01). No statistical change in mtDNA deletion levels was detected;
however, our data indicate that the total mtDNA content decreased with increasing number
Republic (project VH20172020010) (AT), the
Radiation Theme of the Newcastle University and
Public Health of England, Health Protection
Research Unit (HPRU) (CB). The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the
Competing interests: The authors have declared
that no competing interests exist.
of RT fractions. Interestingly, the number of micronuclei appears to correlate with late
radiation toxicity (r2 = 0.9025) in endometrial patients suggesting the possibility of predicting the
severity of RT-related toxicity by monitoring this parameter. Overall, these data represent,
to our best knowledge, the first study providing a multiparametric comparison of radiation
biomarkers in human blood in vivo, which have potential for improving biological dosimetry.
There is an identified need to improve simple and efficient biodosimetric tools that could be
used for triage purposes in public situations such as the screening of potential victims of a
nuclear accident, an act of radiologic terrorism or military conflict [
]. Such tools would also
be of a great use to refine radiation exposure classification in retrospective or large-scale
molecular epidemiology studies where biomarkers of exposure are currently lacking.
In order to assess the level of exposure of individuals, the development of a high-throughput
assay that could process large numbers of samples in a short period is needed. The
conventional methods such as dicentric chromosomes (DC) or micronuclei (MN) assessment are
providing reliable data [
], nevertheless, they are also technically demanding and time consuming
(2±3 days), which is far from optimal for situations with the risk of exposure to ionizing
radiation (IR) when thousands of irradiated persons are expected. In the situations where speed and
throughput are more important than accuracy, it would be extremely helpful to develop other
effective countermeasures for biodosimetric triage. Thus, rapid molecular assays have the
potential to become useful triage tools.
Breakage of cellular DNA following IR exposure occurs in humans within two
interdependent genomes of nuclear and extra-nuclear DNA. Several nuclear DNA-based approaches
have been reported to possess the potential to provide ex-post information regarding exposure
to IR such as scoring gamma-H2AX [
] or monitoring a shift in transcriptional expression of
radiation-responsive genes [4±7]. Manning et al. studied high and low dose responses of
transcriptional biomarkers in ex vivo X-irradiated human blood and found FDXR, DDB2, CCNG1
genes to be suitable transcriptional radiation exposure markers [
]. It has also been recently
shown that the ex vivo irradiated response produces similar dose estimates to in vivo irradiated
patient samples [
Apart from promising gene expression biomarkers, we aimed to investigate the
extranuclear mitochondrial DNA (mtDNA), which was driven by the fact that it is lacking histone
protection and chromatin structure, and its genetic information is more prone to DNA
damage than nuclear DNA. Indeed, mtDNA damage was reported to be more extensive and
transient than nuclear one [
] making it a potentially attractive source of radiation biomarker.
Using several human cell lines, Prithivirajsingh et al. reported significant levels of mtDNA
deletions 72 h following irradiation by doses ranging from 2 to 20 Gy in all of tested cell lines
with lower response in tumor cell lines [
]. However, they reported no consistent dose±
In vivo, evidence was found that radiotherapy (RT) is associated with an increase in
mitochondrial genome mutation rate [
]. Encouragingly, Wen et al. have reported an
increase in mtDNA deletions in peripheral lymphocytes of acute lymphoblastic leukemia
patients undergoing total body irradiation (TBI) therapy [
]. Philips et al. recently reported a
sensitive multiplex real-time polymerase chain reaction (MQRT-PCR) assay for simultaneous
quantification of mitochondrial DNA copy number and deletion ratio for quantification of
2 / 21
An overview of data used for physical dosimetry analyses is given along with radiotoxicity evaluation and cytogenetic data. Diagnosis is provided according to
International Classification of Diseases. Number of micronuclei or dicentrics before RT (control), or after 24 hours (1 RT), 48 hours (2 RT), and 5 weeks (25 RT) is
shown. F = female, M = male.
²Early death of a patient.
mtDNA site in the minor arc (mtMin) where large deletions are rare and another mtDNA site
in the major arc (mtMaj) where large deletions are common. In fact, approximately 84% of
published deletions span the mtMaj target [
]. Thus, using this sensitive assay, we
hypothesized that mtDNA could be a useful indicator of radiation exposure in vivo and we investigated
whether IR induces mtDNA deletions using a specifically designed MQRT-PCR.
Many radiobiological studies are currently focused on identification of novel biomarkers
and their validation [
]. The purpose of this study was to evaluate some new emerging
biomarkers and compare them with the established ones. This study was carried out in circulating
peripheral blood mononuclear cells (PBMC) of oncological patients with indicated RT
undergoing partial body irradiation (PBI) of a large body volume; i.e. ten patients with tumor of
endometrium and eight patients with tumor of head and neck (Table 1). MQRT-PCR provided
simultaneous assessment of mtDNA copy number and proportion of mitochondria genomes
with common deletions. Moreover, we compared the obtained data with analysis of DC and
MN in the same samples. We also provided comparison with monitoring of transcriptional
expression of in vivo validated radiation-responsive genes. Additionally, we determined
changes in apoptotic populations in lymphocytes, lymphocytes and monocytes (PBMC) and
3 / 21
This multiparametric approach allowed us to monitor simultaneously several biomarkers of
radiation exposure, which is, to our best knowledge, the first attempt to provide such a
comparison in human blood samples irradiated in vivo. Besides, the cumulative doses used in this
study reach high levels, therefore we attempted to use particular biomarkers to monitor
radiotherapy responses as well.
Material and methods
Blood samples, physical doses delivered to the patients and radiation
Ten endometrial and eight head and neck oncological patients with indicated PBI without
previous (or concomitant) radio- and chemo-therapy were enrolled in this study (Table 1). Both
patients' subgroups were treated for the same tumor localisation in order to prevent the
variability usually observed among patients treated with RT and to allow the corresponding roles
of the size of irradiation field and of the dose rate.
The informed consent was obtained from each individual and local Ethical Committee of
University Hospital in Hradec Kralove (Czech Republic) approved experimentation with
human subjects according to The Code of Ethics of the World Medical
AssociationÐDeclaration of Helsinki (approval no: 201401-S15P). Ten healthy donors of corresponding age and sex
were used as a control group.
Peripheral blood samples were collected into Li-heparinized tubes (Vacuette, Mundelein,
IL, USA) soon before the first treatment, which served as a control sample for determination
of basal level prior to the radiation and then after 24 h, 48 h, and 5 weeks; i.e. after 1, 2, and 25
fractionated RT procedures (Fig 1). The samples were placed in the fridge and processed for
subsequent cytogenetic analysis within 2 h after collection. The samples for flow-cytometry
were processed directly after sampling. The samples for gene expression analysis were collected
using PAXgene Blood RNA tubes according to the manufacturer's instructions (Qiagen,
PreAnalytiX GmbH, Hilden, Germany).
In the group of endometrial tumor patients, the prescribed dose was 45 Gy within 25 RT
fractions which were applied during 35 days (5 weeks) using LINAC with a dose rate of 300
Fig 1. Experimental design. A scheme of blood sampling and subsequent analyses performed.
4 / 21
MU/min (Varian Medical Systems Inc., Palo Alto, CA, USA) with the treatment planning
system Eclipse (Varian Medical Systems). The single dose per fraction was 1.8 Gy. The average
dose delivered to the blood was calculated as 0.19 Gy per fraction. In the group of head and
neck tumor patients, the prescribed dose was between 50 and 70 Gy within 25 to 33 fractions
applied during 35 to 45 days. The single dose per fraction was 2.0 or 2.121 Gy (Table 1). The
average dose delivered to the blood was calculated as 0.08 Gy per fraction. No shielding was
used for both groups of patients.
Radiation toxicity of treatment was recorded for each patient (Table 1). Acute toxicity
grading was evaluated as the worst grade of toxicity recorded during the treatment or up to 3
months after the end of the treatmentÐCTCAE v. 4.0 grading system was used. The full
definition of the grading system can be found at the RTOG website [
]. Late toxicity grading was
evaluated as the worst grade of symptoms, persisting more than 3 months after the end of the
For this assay, 0.8 ml of heparinized whole blood was utilized. The level of chromosomal
aberrations in peripheral lymphocytes was evaluated by a standardized method based on
microscopic analysis of lymphocytic chromosomes undergoing mitotic metaphase [
whole blood was cultivated and peripheral lymphocytes were stimulated by
phytohemagglutinin (Gibco1, Waltham, MA, USA), treated with colcemid solution (Serva, Heidelberg,
Germany), harvested and stained with Giemsa (Dr. Kulich Pharma, Hradec Kralove, Czech
Republic). In each blood sample, 100 of mitotic sets were evaluated at 100-fold original
magnification and immersion oil. We determined number of DC and structurally aberrant cells. The
protocol is available at https://dx.doi.org/10.17504/protocols.io.mjgc4jw.
For MN assay, 4 ml of blood was used. The lymphocytes were separated from the whole blood
using Histopaque gradient liquid-1077 (Sigma) according to the manufacturerÂs instructions.
After the separation, the cells were cultivated, stimulated with phytohemagglutinin, treated
with cytochalasin B, and stained with Giemsa (all from Sigma) as we previously described in
Kmochova et al. [
]. Stained samples were evaluated using a BX-51 microscope (Olympus,
Prague, Czech Republic) at 40-fold original magnification. For scoring, criteria presented by
Fenech et al. were used [
]. A total of 1000 binucleated cells was evaluated for the frequency
of MN. The protocol is available on-line at https://dx.doi.org/10.17504/protocols.io.mr6c59e.
In apoptosis assessment experiment, 300 μl of heparin (Zentiva, Czech Republic) were added
to peripheral blood obtained from 10 healthy volunteers and radiation exposed patients. The
peripheral blood was kept at the room temperature and lysed by the EasyLyse, erythocyte
lysing reagent (DAKO, Glostrup, Denmark) according to manufacturerÂs instructions. The cell
suspension density was set to 5 x 106 cells/ml in diluted Binding buffer (1:10). Lymphocytes,
lymphocytes and monocytes (PBMC), and granulocytes were stained with monoclonal
antibody Annexin V-FITC (BD Biosciences Pharmingen, San Jose, CA, USA) for 10 min on ice.
Five μl of propidium iodide (250 μg/ml) were added after one washing step in an ice cold
Washing and staining buffer. Data were acquired on CyAn ADP flow cytometer (Beckman
Coulter, Fullerton, CA, USA) and analysis was performed using the Summit v4.3 software
(Beckman Coulter), where lymphocytes, PBMC, and granulocytes were divided based on
forward scatter / side scatter characteristics and cell death was assessed in lymphocytes, PBMC,
5 / 21
and granulocytes populations. The protocol is available on-line at https://dx.doi.org/10.17504/
mtDNA deletions measurement
Genomic DNA from 100 μl of blood was extracted using DNeasy Blood & Tissue Kit according
to the manufacturer's protocol (Qiagen, Hilden, Germany). The measurement of the mtDNA
deletions was done according to protocol published by Phillips et al with minor modifications.
Briefly, 1 ng of DNA from patients was used in the reaction. All reactions were run in triplicate
using PerfeCTa1 MultiPlex qPCR SuperMix (Quanta Biosciences, Inc. Gaithersburg, MD,
USA) with primer and probe sets for target genes at 300 nM concentration each. FAM, HEX
and Texas Red were used as fluorochrome reporters for the hydrolysis probes analysed in
multiplexed reaction. Cycling parameters were 10 min at 95ÊC, then 40 cycles of 10 s at 95ÊC and
60s at 60ÊC. Data were collected and analysed by Rotor-Gene Q Series Software. Ct values
were converted to ng using standard curves obtained by serial dilution of a control DNA
sample. The linear dynamic range of the standard curves ranging from 17 ng to 66 pg gave PCR
efficiencies between 93% and 103% for each assay with R2 > 0.998. Values for mitochondrial
mtMaj and mtMin assays were normalized to genomic beta-2-microglobulin (B2M) internal
control. The protocol including the sequences of primers and Locked Nucleic Acid (LNA)
TaqMan probes is available at https://dx.doi.org/10.17504/protocols.io.mpqc5mw.
Blood samples were collected from the radiotherapy treated cancer patients in PAXGene tubes
according to the manufacturer's protocol (Qiagen, PreAnalytiX GmbH, Hilden, Germany).
The tubes were kept at RT for 2 hr before being frozen at -20ÊC. RNA was extracted from the
samples using the PAXGene Blood miRNA Kit (Qiagen, PreAnalytiX GmbH, Hilden,
Germany) according to the manufacturer's protocol. RNA quantity was assessed by Nanodrop
ND2000 (Nanodrop, Wilmington, USA), and RNA quality was assessed by RIN values
produced by Tapestation 2200 (Agilent Technologies, CA, USA).
Reverse transcriptase reactions were performed using High Capacity cDNA Reverse
transcription kit (Applied Biosystems, FosterCity, CA, USA) according to the manufacturer ` s protocol
with 350 ng of total RNA. Multiplex quantitative RT-PCR Real-time PCR was performed
using Rotor-Gene Q (Qiagen, Hilden, Germany). All reactions were run in triplicate using
PerfeCTa1 MultiPlex qPCR SuperMix (Quanta Biosciences, Inc. Gaithersburg, MD, USA) with
primer and probe sets for target genes at 300 nM concentration each. 3 0 6-Carboxyfluorescein
(FAM), 6-Hexachlorofluorescein (HEX), Texas Red and CY5 (all from Eurogentec Ltd,
Fawley, Hampshire, UK) were used as fluorochrome reporters for the hydrolysis probes analysed
in multiplexed reactions with between 2 and 4 genes per run including the control. Cycling
parameters were 2 min at 95ÊC, then 45 cycles of 10 s at 95ÊC and 60 s at 60ÊC. Data were
collected and analyzed by Rotor-Gene Q Series Software. Gene target Ct (cycle threshold) values
were normalized to a Hypoxanthine-Guanine phosphoribosyltransferase 1 (HPRT1) internal
control. Primer and probe designs can be found in our previous work, Kabacik et al. [
values were converted to transcript quantity using standard curves obtained by serial dilution
of PCR-amplified DNA fragments of each gene. The linear dynamic range of the standard
curves covering six orders of magnitude (serial dilution from 3.2 x 10−4 to 8.2 x a10-10) gave
PCR efficiencies between 93% and 103% for each gene with R2 > 0.998. Relative gene
expression levels after irradiation were determined relative to unexposed controls.
6 / 21
The protocol including primers/probes sequences is available on-line at https://dx.doi.org/
Physical dosimetry calculations
To determine the Mean dose of the irradiated blood sample of patients undergoing RT, the
treatment planning system Eclipse was used, i.e. a software frequently used in external beam
planning. This system uses the Anisotropic Analytical Algorithm to compute 3D dose
distribution in patient's volume. The software displays the geometry of the patient acquired by
computed tomography and computed dose distribution. From these data Irradiated Volume (IV)
defined as a volume surrounded by five percent isodose and Mean dose in this volume (Dmean)
were determined for each patient. Five percent isodose is the surface that connects points in
3D dose distribution where the dose is equal to 5% of the prescribed dose. It was used in order
to increase consistency of the data, since the CT scans covered different body parts. Thus, for
the calculation purposes, doses lower than 5% of the prescribed dose were not taken into
account. In the following relation, we assume that the blood in the patient's body is irradiated
homogeneously, the blood is stored in the human body homogeneously and 1 dm3 of human
body weighs approximately 1 kg. Mean dose in the patient's blood (MBD) was calculated
according to the relation:
MBD Dmean: IBV
MBD Dmean: IV
MBDÐmean blood dose; DmeanÐirradiated volume mean dose; IBVÐirradiated blood
volume; IVÐirradiated volume; BBVÐbody blood volume; VÐtotal patient volume
(approximated to patient's weight).
Statistical analysis of the biological data was performed using Minitab 17 (Minitab Ltd.,
Coventry, UK) and SPSS Statistics v24 (IBM, Armonk, NY, USA). Data points represent the
mean ± SEM. All data were tested for normal distribution using Shapiro-Wilk test.
For analysis of MN data, Mann±Whitney test was used. Changes were considered
statistically significant with p < 0.001.
For analysis of DC data, ANOVA was used for normal variables and Kruskal-Wallis test
was used for non-normal variables. Next, univariate General Linear Model based on Hermite
distribution was adjusted for the count of DC (response variable) by number of RT fractions
(explanatory variable). Changes were considered statistically significant with p < 0.01.
For analysis of QRT-PCR data, paired t-test was applied. When normality test failed
MannWhitney rank sum test was used with p < 0.01 or p < 0.005, respectively.
The dose estimates were performed as described in Abend et al. [
The number of chromosomal changes in PBMCs of head and neck patients
increased with number of RT fractions
We determined the number of DC per 100 cells and percentage of structurally aberrant cells
in head and neck patients. We found the number of dicentrics at time 0, and after 1st, 2nd,
7 / 21
Fig 2. Chromosomal changes in PBMCs of head and neck patients. Number of dicentric chromosomes (A) and
structurally aberrant cells (B) was determined and both parameters increase with the number of RT fractions. ,
statistically significant difference versus Control group (p < 0.01). Representative figures of dicentric chromosome (C)
and structurally aberant cellsÐring chromosome (D), double fragment (E) and break (F) are shown.
and 25th RT fractions, to be 1.5, 7.0, 9.0, and 12.5, respectively. The proportion of
chromosomal aberrant cells (SAC) was 6, 11, 15, and 18%, respectively (Fig 2). The increase in the
number of DC and SAC was significant in all groups when compared to the control group
The number of micronuclei in PBMCs of endometrial patients increased
with number of RT fractions
We assessed the number of MN in ten endometrial patients at time 0 (27,40 ± SEM 4,45) and
after 1st (31.60 ± 4.74), 2nd (38.10 ± 6.01), and 25th (149.10 ± 37.33) RT fractions, respectively
(Fig 3A). We observed statistically significant increase in the number of MN after the 2nd and
25th fraction when compared to the control group (p < 0.001). The increase after the 25th RT
fraction was also statistically significant when compared with the 2nd RT fraction group
(p < 0.001).
8 / 21
Fig 3. Incidence of micronuclei in PBMCs of endometrial patients (A) and their relation to late radiotoxicity (B). Number of MN increased with the number
of RT fractions. BN, binucleated cells; , statistically significant difference of the 2nd and 25th RT fraction versus Control group (p < 0.001); #, statistically
significant difference of the 25th RT fraction versus 2nd RT fraction (p < 0.001).
Micronuclei could have potential for late radiotoxicity prediction
We evaluated late toxicity grading as the worst grade of symptoms persisting more than 3
months after the end of the treatment as described in Manning et al. [
]. Here we correlated
our data with incidence of MN (Fig 3B). Eight out of ten patients exhibited late radiotoxicity
graded 0 or 1. However, patients E7 and E9 suffered from late radiotoxicity effects (grade 4
and 3, respectively) and the highest number of MN we detected (206 and 199, respectively)
corresponded with these patients. Although a larger group of patients would be required in
order to confirm this conclusion, our results suggest that late radiation toxicity in endometrial
patients might be associated with increased number of MN (correlation coefficient r2 = 0.902).
The ratio of damaged cells in lymphocytes, PBMC, and granulocytes
populations of both endometrial and head and neck patients did not
changed throughout the whole study period
We measured the percentage of damaged cells, i.e. early apoptotic cells (Annexin V-positive/
propidium iodide-negative), late apoptotic (Annexin V-positive/propidium iodide-positive),
and necrotic (Annexin V-negative/propidium iodide-positive in lymphocytes, PBMC, and
granulocytes population, respectively, by flow cytometry and observed no statistically
significant change in both groups of endometrial and head and neck patients throughout all time
intervals (Fig 4A and 4B). Interestingly, the proportion of necrotic cells in head and neck
patients increased significantly at the end of therapy (after 25th RT fraction) in all
sub-populations when compared to the Control group (p < 0.05).
The amount of mtDNA content decreased by time after irradiation
The level of reference gene B2M (measured DNA concentration in ng) was not changed
during the studied time-points and we observed no time-dependent changes in mtDNA deletions.
On the other hand, we observed statistically significant difference (p 0.05) of relative
mtDNA content (mtMinArchand mtMajArch ratio) between control and 25th RT fraction.
9 / 21
Fig 4. The relative proportion of early apoptotic, late apoptotic, and necrotic cells. The relative proportions of early
apoptotic (Annexin V-positive/propidium iodide-negative), late apoptotic (Annexin V-positive/propidium
iodidepositive), and necrotic cells (Annexin V-negative/propidium iodide-positive) were determined (all combined set as
100%) in PBMC, granulocytes, and lymphocytes populations of endometrial (A) and head and neck patients (B). None
of them showed a statistically significant change, but the necrotic population in head and neck patients after 25 RT
fractions. See S1 Fig for gating strategy. , statistically significant difference of the 25th RT fraction versus Control
group (p < 0.05).
10 / 21
Fig 5. The amount of mtDNA content. mtDNA was quantified in the minor arc (mtMin) and in the major arc (mtMaj) site. The data indicate the relative
decrease in mtDNA content over the time in both groups of the endometrial (A) and (B) and head and neck (C) and (D) patients. Upper and lower quartiles with
median are shown. Black rhombs represent arithmetic mean; , statistically significant difference between 25th RT fraction and Control group (p < 0.05).
Our data indicate that the relative mtDNA content decreased over the time in both groups of
the endometrial (Fig 5A and 5B) and head and neck patients (Fig 5C and 5D) after 25th RT
fraction versus control time-point.
Transcriptional modification of expression in vivo of radiation-responsive
Previously reported radiation responsive genes PHPT1, CCNG1, CDKN1A, GADD45, and
] were investigated in blood samples from RT patients to validate them in vivo for
use in biodosimetry assays at early time-points (24 and 48 h) following one and two dose
exposures, respectively. We also monitored the expression of these genes after the final RT fraction
(5 weeks after the start of the RT treatment).
11 / 21
Fig 6. Transcriptional modification of expression of radiation-responsive genes in endometrial patients. Transparent symbols represent QRT-PCR fold
change in expression of the genes PHPT (A), CCNG1 (B), CDKN1A (C), GADD45 (D), and SESN1 (E) for ten individual endometrium cancer patients before (0)
and after 1, 2, and 25 fractions of radiotherapy (RT). The mean (± SEM) is shown as non-transparent symbols. Gene expression is given as fold change relative to
unexposed Control sample set at 1 (normalized against the housekeeping gene, HPRT). , statistically significant difference versus Control group (p < 0.01); ,
statistically significant difference versus Control group (p < 0.005).
Overall, an up-regulation of PHPT1, CCNG1, CDKN1A, GADD45, and SESN1 was found
in endometrial (Fig 6) and head and neck cancer patients (Fig 7) at all time points with the
exception of SESN1. It showed a significant up-regulation at 48 h followed by a
down-regulation becoming significant for endometrial patients following the 25th RT fraction (Fig 6E). For
many of the genes, the transcriptional response was more pronounced in endometrial cancer
patients, who received a higher fractional dose to the blood. Hence, PHPT1 and CDKN1A
were significantly up-regulated at all time points in endometrial patients (Fig 6A and 6C,
respectively) while a significant up-regulation in head and neck cancer patients was observed
for PHPT1 and CDKN1A only at 48 hr, after the 2nd RT fraction (Fig 7A and 7C, respectively).
CCNG1 (Cyclin G1) showed an up-regulation significant in the endometrial cancer patient
group (Fig 6B) at the early time-points of 24 hr and 48 hr while in the head and neck cancer
12 / 21
Fig 7. Transcriptional modification of expression of radiation-responsive genes in head and neck patients. Transparent symbols represent QRT-PCR fold
change in expression of the genes PHPT (A), CCNG1 (B), CDKN1A (C), GADD45 (D), and SESN1 (E) for eight head and neck cancer patients before (0) and after
1, 2, and 25 fractions of radiotherapy (RT). The mean (± SEM) is shown as non-transparent symbols. Gene expression is given as fold change relative to unexposed
Control sample set at 1 (normalized against the housekeeping gene, HPRT). , statistically significant difference versus Control group (p < 0.01); , statistically
significant difference versus Control group (p < 0.005). For GADD45 p-trend was applied (r2 = 0.980).
patients we detected up-regulations that were not statistically significant (Fig 7B). These genes
therefore seem particularly suited for biodosimetry with an up-regulation 24 hr following a
partial body exposure. GADD45 behaved slightly differently as the up-regulation observed was
significant at the latest time-point specifically and only in the endometrial group (Fig 6D)
although a similar trend could be observed in the head and neck group (Fig 7D) with r2 =
0.980. The gene SESN1, Sestrin 1 (Figs 6E and 7E), demonstrated a clearly different pattern of
expression as the up-regulation seen at 48 hr was followed by a down-regulation found
significant in the endometrial group following the 25th RT fraction (Fig 6E); a similar trend could be
observed in the head and neck group.
13 / 21
In case of a large-scale radiological event, the subsequent medical management would strongly
rely on triage of potentially exposed individuals. This can be achieved by assessing clinical
signs and/or symptoms indicating severe exposure [
], however, procedures for
determination of low doses are not fully developed and current biodosimetry suffers from certain gaps in
the methodology [
] in the terms of sensitivity, limited high-throughput capacity etc. In this
study, we wanted to compare different biomarkers of radiation exposure. To this end, we
performed in vivo analysis of cytogenetic parameters, gene expression and mtDNA in oncological
patients undergoing PBI.
So far, the ªgold standardº of biological dosimetry is the dicentric chromosomal aberration
assay. DC, rings, and fragments are generally considered as radiation-specific and these types
of aberrations are referred to as unstable because their persistence in the body declines with
cell division cycles [
]. In vivo, Matsuoka et al. detected chromosomal aberrations in
lymphocytes from patients with tumors of stomach, prostate, lung, or hepatocellular carcinoma, who
received high doses of therapeutic X-rays [
]. Many other studies have confirmed cytogenetic
assays as valid tools for application in biodosimetry [25±27] and later, the high throughput
capacity of this assay for triage purposes in the web-based scoring mode was suggested [
In this study, due to time and staff limitations we had to perform cytogenetic analysis in
different laboratories, while each of them relied on different methodology (i.e. DC versus MN).
Therefore, we analysed DC only in head and neck and MN in endometrial patients.
As expected, we found the number of DC as well as the number of chromosomal
aberrations increasing in all head and neck tumor patients after the 1st and the 2nd RT fraction. The
significant increase was observed also after 5 weeks, i.e. in the end of the therapy (25 RT
fractions). Similar study was performed by Roch-Lefèvre et al. with eight patients treated for head
and neck cancer, who observed a significant increase in the cytogenetic markers
MN are formed during the metaphase/anaphase transition of mitosis and its scoring can be
performed relatively easily and on different human cell types relevant for biomonitoring.
Regarding the workload, this assay is much faster than DC analysis. The number of MN in
PBMCs of endometrial patients increased significantly after each RT fraction that we
examined. Similarly, Silva-Barbosa et al. assessed five uterine cancers patients irradiated by the
absorbed dose of 0 Gy, 0.08 Gy, and 1.8 Gy, respectively, and found statistical increase in DC
and MN, respectively [
]. A significant work has been conducted in the area of MN analysis
and high-throughput biodosimetry by Dr. Brenner's group [
], who recently reported an
implementation of commercial robotic high-throughput screening system for large-scale
radiological incidents .
In summary, based on results from cytogenetic analysis we conclude that the doses applied
to PBI patients were high enough to produce a response on cytogenetic level. Unfortunately,
our efforts to provide dose estimates from DC data were not successful due to large
uncertainties including inter-individual variance and overdispersion, thus it was not possible to form
any conclusions here.
In the terms of apoptosis induction, we aimed to measure damaged (not healthy) cells by
flow cytometry and determined the relative proportion of early apoptotic, late apoptotic, and
necrotic cells in lymphocytes, PBMC, and granulocytes population, respectively, and observed
no statistically significant changes in both groups of patients throughout all time intervals.
This was probably due to elimination of damaged cells by mononuclear phagocyte system. The
immediate clearance of apoptotic cells by macrophages is crucial to inhibit inflammation and
autoimmune responses and possibly did not allow us to monitor any changes [
14 / 21
In this study, novel quantitative biodosimetric assays were compared using in vivo blood
samples of RT-treated patients against the golden standard methods. This study was
performed as a one-year pilot and the low number of patients is a drawback. Nevertheless, such
experiment is unique as to our best knowledge only one group reported assessment of mtDNA
content as a marker of irradiation in humans in vivo. Wen et al. screened gene expression
profiles of peripheral lymphocytes [
], but involved TBI patients irradiated with fairly high
doses. The samples were taken 24 h after two RT sessions of 4.5 Gy over two successive days (9
Gy in total) from four adult acute lymphoid leukaemia patients. They observed 478
significantly expressed genes and identified three unique patterns. Furthermore, Wen et al. studied
mtDNA content and common deletion levels in another set of 26 TBI patients by quantitative
PCR. They reported significant modifications of both parameters and proposed them as
predictive factors to radiation toxicity [
]. However, in our conditions we did not find any
significant change in mtDNA deletion, possibly because we used PBI patients with lower mean
blood doses. Nevertheless, we observed a time-dependent decrease in total mtDNA content in
both groups of the PBI patients consistent with a detrimental radiation effect on lymphocytes
We and others have previously reported several radiation-responsive candidate genes
potentially suitable for biological dosimetry purposes in several publications [4±7,35,36], but
more has to be learnt about their applicability under in vivo conditions when applied to
differentially exposed individuals. For example, FDXR is a well-known radiation responsive gene
that has been formerly investigated for use in biodosimetry [
] but data obtained in regards
to this gene will be presented elsewhere. Thus, here we aimed to assess and potentially validate
in vivo the following genes previously identified after ex vivo exposure: PHPT1, CCNG1,
CDKN1A, GADD45, and SESN1.
Overall, the genes that we studied in vivo in RT patients followed the same pattern of
transcriptional expression in both groups of PBI patients, but the transcriptional response was
more pronounced in endometrial cancer patients, compared to the head and neck patients.
One possible explanation is that the irradiated volume is smaller in head and neck patients (i.e.
in average 1.1 ± 0.17 versus 0.5 ± 0.11 dm3) and this is consistent with a lower dose to the
blood and the lower doses delivered (i.e. mean dose per fraction 0.188 ± 0.20 versus 0.092 ±
0.012 Gy). We conclude that CDKN1A, CCNG1, and PHPT1 are particularly suitable for
biodosimetry with an up-regulation at early time-points.
Amongst the five genes analysed, four of them, CCNG1, CDKN1A, GADD45 and SESN1 are
known to be transcriptionally regulated (at least partially) by the tumor suppressor protein
p53. Expression of CDKN1A, also known as cell cycle inhibitor p21, is controlled by p53 in
response to multiple stress stimuli such as DNA damage following radiation exposure. It is
tempting to suggest that its persistent up-regulation at the transcriptional level might be due to
genomic instability in cell mitochondria as shown by the decrease in total mtDNA content we
reported although no mitochondrial deletions were found. CDKN1A up-regulation is
significantly maintained throughout the treatment in both sets of patients and, although this was
following 25 fractions of radiotherapy, it could potentially be useful for follow-up/retrospective
biodosimetry. However, the expression of CDKN1A has also been associated with normal
tissue sensitivity to RT [
] and its response has been variable in ex vivo irradiated blood samples
Similarly to CDKN1A, GADD45 (coding for Growth arrest and DNA damage-inducible 45
protein) expression level is clearly up-regulated after the 25th fraction, while perhaps
surprisingly SESN1 is down-regulated significantly in endometrial patient blood (with a similar
pattern in head and neck patients) at this final time-point. SESN1 codes for sestrin 1, which plays
a role in the cellular response to DNA damage and the oxidative stress response; the
down15 / 21
regulation towards the end of the treatment perhaps might be related to the cumulative doses
and a chronic oxidative stress.
In addition, the gene PHPT1 (phosphohistidine phosphatase 1, the only one known in
mammals) is, alongside CDKN1A, consistently up-regulated in both sets of patients. This gene
regulates the phosphohistidine levels of several proteins including those involved in cell
signalling, lipid metabolism, and potassium ion transport [
]. Perhaps it is therefore not surprising
that it is up-regulated in lymphocytes following radiation exposure. Our results suggest that it
is a strong candidate for biological dosimetry purposes.
CCNG1 codes for cyclin G1 regulating cyclin-dependent protein kinases, which control cell
cycle. We found CCNG1 up-regulated only in endometrial patients. Up-regulation was not
significant towards the end of RT, making it suitable for biodosimetry of single exposures.
Importantly, we performed dose estimates on the gene expression data generated; however,
they were quite variable amongst patients. We did not observe any increase in dose estimate
with increasing dose to the blood and the dose estimates were sometimes high in the
pre-exposure controls. The best gene for dose estimates was GADD45 but even then it did not exhibit a
significant correlation between the dose and its expression. Although the data were not
included here, a comparison with other radiation-responsive genes would be needed to
identify the best biomarkers of exposure in in vivo samples. So far, we suggest that the best
candidate gene for biological dosimetry proposed by our group would still be FDXR as reported
] due to high linear-dynamic range and low inter-individual variance.
It should be noted that the role of potential confounding factors such as age and gender (in
case of head and neck patients) could not be evaluated due to limited sample size but would be
of importance for the future studies. Several studies suggested the use of different biomarkers
as potential tools for normal tissue response prediction. As the cumulative doses used in this
study reach high levels, tools such as this could be used to monitor radiotherapy responses as
well. Although our data would require confirmation and extension, it indicate that late
radiation toxicity in RT patients might be associated with MN increase, which would support the
use of MN as cytogenetic predictive markers for clinical radiosensitivity and underlie a
prognostic role of such biological parameter for patients' follow-up. It should be noted that we
evaluated response to fractionated doses. Thus, the translation of our findings to a single dose
scenario is limited but still it is the only feasible way of conducting such study in humans.
Above that, this is the first attempt to compare several cellular and molecular radiation
biomarkers in human peripheral blood irradiated in vivo in the same patients in a single study.
Combining emerging and established biomarkers has the potential to provide more accurate
monitoring of individual response to IR exposure and possibly, to contribute to assessment of
the radiation toxicity and long term effects. Based on our data, we constructed graphs showing
the induction and temporal persistence of the biomarkers studied here (Fig 8). Zeegers et al.
compared suitability of different current biodosimetric markers. Although they performed
their study on a cell line and not in vivo they conclusions strongly encouraged the idea of
employing a multiparametric approach for dose/risk estimation [
Overall, in the case of PBI and multiple fractions it appears that early-time points are better
monitored by radiation induced genes than the later time-points where the use of cytogenetic
markers might be more beneficial.
In summary, the results discussed here represent the first study of its kind that used in vivo
model of PBI oncological patients undergoing RT to compare several divergent cellular and
molecular biomarkers of radiation exposure.
16 / 21
Fig 8. Induction and persistence of different biomarkers. Graphs showing the induction and temporal persistence of the biomarkers
studied in endometrial (A) and head and neck patients (B). In order to compare all the parameters studied, the highest value detected
was arbitrary set as 100%. Established cytogenetic markers and mtDNA content are suitable for late time points after irradiation while
the new biomarkers as radiation-induced genes are more informative atearly time-points after radiation exposure. mt Maj, data from
mtDNA content analysis of mtMajArch; mt Min, data from mtDNA content analysis of mtMinArch; gene expression, data from
MQRT-PCR (average of five genes); micronuclei, data from micronuclei assay; aberrations, data from structural aberration analyses;
dicentrics, data from dicentric chromosomes assay; apoptosis, data from flow-cytometric detection of apoptotic cells in lymphocyte
population (percentage of apoptotic cells versus healthy-intact cells set as 100%).
17 / 21
Cytogenetic data confirmed the expected dose-dependent increase in DC and induction of
MN in PBMCs. Similarly, increasing the number of RT fractions led to a decrease in mtDNA
content. Thus, we suggest that although we were not able to confirm mtDNA content to have a
potential as biomarker of a single radiation exposure, we suggest that more work should be
carried out to confirm that it could be of importance in situations following multiple fraction
doses and that its decrease might have physiological consequences. Finally, monitoring the
transcription of five genes previously identified in ex vivo experiments as radiation responsive,
highlighted the sensitivity and consistency across individuals of these biomarkers.
It seems that established cytogenetic markers (DC and MN) and mitochondrial DNA
content are suitable for later time points after irradiation while the new biomarkers as
radiationinduced genes are suitable for rapid monitoring of early time-points after radiation exposure.
Importantly, growing evidence indicates the upcoming trend in research of indicators of
ionising radiation effects. It will involve a combination of established and emerging
biomarkers and our study provides a platform for future work in this area. Among these biomarkers,
some have the potential for use in radiation oncology as they can be easily monitored during
the course of the RT treatment.
S1 Fig. Gating strategy for flow-cytometry (Annexin V) experiment. (A) Dot plot analysis
shows the region of lymphocytes (R1), PBMC (R2) and granulocytes (R3) based on their
forward scatter (FSC) and side scatter (SSC) characteristic. (B) Dot plot analysis of
lymphocytes (R1 region) shows intact cells (Annexin V-negative, PI-negative), early apoptotic cells
(Annexin V-positive, PI-negative), apoptotic cells (Annexin V-positive and PI-positive) and
necrotic cells (Annexin V-negative, PI-positive) in the peripheral blood of PBI patient. (C) Dot
plot analysis of PBMC (R2 region) shows intact cells (Annexin V-negative, PI-negative), early
apoptotic cells (Annexin V-positive, PI-negative), apoptotic cells (Annexin V-positive and
PIpositive) and necrotic cells (Annexin V-negative, PI-positive) in the peripheral blood of PBI
patient. (D) Dot plot analysis of granulocytes (R3 region) shows intact cells (Annexin
V-negative, PI-negative), early apoptotic cells (Annexin V-positive, PI-negative), apoptotic cells
(Annexin V-positive and PI-positive) and necrotic cells (Annexin V-negative, PI-positive) in
the peripheral blood of PBI patient.
Conceptualization: Ales Tichy, Andrea Malkova, Marie Davidkova, Eileen Pernot, Elisabeth
Cardis, Christophe Badie.
Data curation: Ales Tichy, Sylwia Kabacik, Grainne O'Brien, Jaroslav Pejchal, Zuzana
Sinkorova, Adela Kmochova, Igor Sirak, Jakub Grepl, Matthaeus Majewski, Elizabeth Ainsbury,
Lenka Zarybnicka, Jana Vachelova, Alzbeta Zavrelova, Marketa Markova Stastna, Michael
Abend, Christophe Badie.
Formal analysis: Ales Tichy, Zuzana Sinkorova, Juan Ramon Gonzalez, Jakub Grepl,
Matthaeus Majewski, Elizabeth Ainsbury, Michael Abend, Christophe Badie.
Funding acquisition: Ales Tichy, Eileen Pernot, Elisabeth Cardis, Christophe Badie.
Investigation: Ales Tichy, Sylwia Kabacik, Grainne O'Brien, Jaroslav Pejchal, Caterina Gomila
Beltran, Christophe Badie.
18 / 21
Methodology: Ales Tichy, Grainne O'Brien, Jaroslav Pejchal, Elisabeth Cardis, Christophe
Project administration: Ales Tichy.
Supervision: Ales Tichy, Igor Sirak, Elisabeth Cardis, Christophe Badie.
Writing ± original draft: Ales Tichy, Christophe Badie.
Writing ± review & editing: Ales Tichy, Christophe Badie.
19 / 21
20 / 21
1. Blakely WF , Salter CA , Prasanna PGS . Early-response biological dosimetryÐrecommended countermeasure enhancements for mass-casualty radiological incidents and terrorism . Health Phys . 2005 ; 89 : 494 ± 504 . PMID: 16217193
2. Chaudhry MA . Biomarkers for human radiation exposure . J Biomed Sci . 2008 ; 15 : 557 ± 563 . https://doi. org/10.1007/s11373-008-9253-z PMID: 18454354
3. Rothkamm K , Beinke C , Romm H , Badie C , Balagurunathan Y , Barnard S , et al. Comparison of established and emerging biodosimetry assays . Radiat Res . 2013 ; 180 : 111 ± 119 . https://doi.org/10.1667/ RR3231.1 PMID: 23862692
4. Kabacik S , Mackay A , Tamber N , Manning G , Finnon P , Paillier F , et al. Gene expression following ionising radiation: identification of biomarkers for dose estimation and prediction of individual response . Int J Radiat Biol . 2011 ; 87 : 115 ± 129 . https://doi.org/10.3109/09553002. 2010 .519424 PMID: 21067298
5. Manning G , Kabacik S , Finnon P , Bouffler S , Badie C . High and low dose responses of transcriptional biomarkers in ex vivo X-irradiated human blood . Int J Radiat Biol . 2013 ; 89 : 512 ± 522 . https://doi.org/10. 3109/09553002. 2013 .769694 PMID: 23362884
6. Badie C , Kabacik S , Balagurunathan Y , Bernard N , Brengues M , Faggioni G , et al. Laboratory intercomparison of gene expression assays . Radiat Res . 2013 ; 180 : 138 ± 148 . https://doi.org/10.1667/RR3236. 1 PMID: 23886340
7. Abend M , Badie C , Quintens R , Kriehuber R , Manning G , Macaeva E , et al. Examining RadiationInduced In Vivo and In Vitro Gene Expression Changes of the Peripheral Blood in Different Laboratories for Biodosimetry Purposes: First RENEB Gene Expression Study . Radiat Res . 2016 ; 185 : 109 ± 123 . https://doi.org/10.1667/RR14221.1 PMID: 26829612
8. Manning G , Macaeva E , Majewski M , Kriehuber R , BrzoÂska K , Abend M , et al. Comparable dose estimates of blinded whole blood samples are obtained independently of culture conditions and analytical approaches. Second RENEB gene expression study . Int J Radiat Biol . 2017 ; 93 : 87 ± 98 . https://doi.org/ 10.1080/09553002. 2016 .1227105 PMID: 27626709
9. Yakes FM , Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress . Proc Natl Acad Sci U S A . 1997 ; 94 : 514 ± 519 . PMID: 9012815
10. Prithivirajsingh S , Story MD , Bergh SA , Geara FB , Ang KK , Ismail SM , et al. Accumulation of the common mitochondrial DNA deletion induced by ionizing radiation . FEBS Lett . 2004 ; 571 : 227 ± 232 . https:// doi.org/10.1016/j.febslet. 2004 . 06 .078 PMID: 15280047
11. Guo Y , Cai Q , Samuels DC , Ye F , Long J , Li C-I , et al. The use of next generation sequencing technology to study the effect of radiation therapy on mitochondrial DNA mutation . Mutat Res . 2012 ; 744 : 154 ± 160 . https://doi.org/10.1016/j.mrgentox. 2012 . 02 .006 PMID: 22387842
12. Wen Q , Hu Y , Ji F , Qian G . Mitochondrial DNA alterations of peripheral lymphocytes in acute lymphoblastic leukemia patients undergoing total body irradiation therapy . Radiat Oncol Lond Engl . 2011 ; 6 : 133 . https://doi.org/10.1186/ 1748 -717X- 6 -133 PMID: 21978541
13. Phillips NR , Sprouse ML , Roby RK . Simultaneous quantification of mitochondrial DNA copy number and deletion ratio: a multiplex real-time PCR assay . Sci Rep . 2014 ; 4 : 3887 . https://doi.org/10.1038/ srep03887 PMID: 24463429
14. Badie C , Hess J , Zitzelsberger H , Kulka U. Established and Emerging Biomarkers of Radiation Exposure. Clin Oncol . 2016 ; 28 : 619 ± 621 . https://doi.org/10.1016/j.clon. 2016 . 06 .002 PMID: 27401968
15. RTOG website [Internet]. https://www.rtog.org/ResearchAssociates/AdverseEventReporting.aspx
16. CernaÂ M , SpĕvaÂckovaÂ V , BataÂriovaÂ A , SmÂõd J , CejchanovaÂ M , OcadlÂõkovaÂ D , et al. Human biomonitoring system in the Czech Republic . Int J Hyg Environ Health . 2007 ; 210 : 495 ± 499 . https://doi.org/10. 1016/j.ijheh. 2007 . 01 .005 PMID: 17296328
17. Kmochova A , Tichy A , Zarybnicka L , Sinkorova Z , Vavrova J , Rehacek V , et al. Modulation of ionizing radiation-induced effects by NU7441, KU55933 and VE821 in peripheral blood lymphocytes . J Appl Biomed . 2016 ; 14 : 19 ± 24 . https://doi.org/10.1016/j.jab. 2015 . 07 .001
18. Fenech M. Cytokinesis-block micronucleus assay evolves into a ªcytomeº assay of chromosomal instability, mitotic dysfunction and cell death . Mutat Res Mol Mech Mutagen . 2006 ; 600 : 58 ± 66 . https://doi. org/10.1016/j.mrfmmm. 2006 . 05 .028 PMID: 16822529
19. Manning G , TichyÂ A , SiraÂk I , Badie C . Radiotherapy-Associated Long-term Modification of Expression of the Inflammatory Biomarker Genes ARG1, BCL2L1, and MYC. Front Immunol . 2017 ; 8 : 412 . https:// doi.org/10.3389/fimmu. 2017 .00412 PMID: 28443095
20. Paul S , Amundson SA . Development of gene expression signatures for practical radiation biodosimetry . Int J Radiat Oncol Biol Phys . 2008 ; 71 : 1236 ± 1244 . https://doi.org/10.1016/j.ijrobp. 2008 . 03 .043 PMID: 18572087
21. Port M , Pieper B , Knie T , DoÈrr H , Ganser A , Graessle D , et al. Rapid Prediction of Hematologic Acute Radiation Syndrome in Radiation Injury Patients Using Peripheral Blood Cell Counts . Radiat Res . 2017 ; 188 : 156 ± 168 . https://doi.org/10.1667/RR14612.1 PMID: 28590841
22. Vinnikov VA . Optimizing the Microscopy Time Schedule for Chromosomal Dosimetry of High-dose and Partial-body Irradiations . Genome Integr . 2017 ; 8 . https://doi.org/10.4103/2041- 9414 .198908 PMID: 28250910
23. Fernandes TS , Loyd DC , Amaral A . Biodosimetry for dose assessment of partial-body exposure: a methodological improvement . Braz Arch Biol Technol . 2008 ; 51 : 97 ± 102 . https://doi.org/10.1590/ S1516-89132008000700016
24. Matsuoka A , Yamada K , Hayashi M , Sofuni T. Chromosomal aberrations detected by chromosome painting in lymphocytes from cancer patients given high doses of therapeutic X-rays . J Radiat Res (Tokyo) . 1996 ; 37 : 257 ± 265 .
25. Carbonell F , Ganser A , Fliedner TM , Arnold R , Kubanek B. The fate of cells with chromosome aberrations after total-body irradiation and bone marrow transplantation . Radiat Res . 1983 ; 93 : 453 ± 460 . PMID: 6344124
26. Sreedevi B , Rao BS , Nagaraj H , Pal NK . Chromosome aberration analysis in radiotherapy patients and simulated partial body exposures: biological dosimetry for non-uniform exposures . Radiat Prot Dosimetry . 2001 ; 94 : 317 ± 322 . PMID: 11499434
27. Gershkevitsh E , Hildebrandt G , Wolf U , Kamprad F , Realo E , Trott K -R. Chromosomal aberration in peripheral lymphocytes and doses to the active bone marrow in radiotherapy of prostate cancer . Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al . 2002 ; 178 : 36 ± 42 .
28. Roch-Lefèvre S , Pouzoulet F , Giraudet AL , Voisin P , Vaurijoux A , Gruel G , et al. Cytogenetic assessment of heterogeneous radiation doses in cancer patients treated with fractionated radiotherapy . Br J Radiol . 2010 ; 83 : 759 ± 766 . https://doi.org/10.1259/bjr/21022597 PMID: 20739344
29. Silva-Barbosa I , Pereira-Magnata S , Amaral A , Sotero G , Melo HC . Dose assessment by quantification of chromosome aberrations and micronuclei in peripheral blood lymphocytes from patients exposed to gamma radiation . Genet Mol Biol . 2005 ; 28 : 452 ± 457 . https://doi.org/10.1590/S1415- 47572005000300021
30. Lue SW , Repin M , Mahnke R , Brenner DJ . Development of a High-Throughput and Miniaturized Cytokinesis-Block Micronucleus Assay for Use as a Biological Dosimetry Population Triage Tool . Radiat Res . 2015 ; 184 : 134 ± 142 . PMID: 26230078
31. Bertucci A , Smilenov LB , Turner HC , Amundson SA , Brenner DJ . In vitro RABiT measurement of dose rate effects on radiation induction of micronuclei in human peripheral blood lymphocytes . Radiat Environ Biophys . 2016 ; 55 : 53 ± 59 . https://doi.org/10.1007/s00411-015-0628-z PMID: 26791381
32. Repin M , Pampou S , Karan C , Brenner DJ , Garty G. RABiT-II: Implementation of a High-Throughput Micronucleus Biodosimetry Assay on Commercial Biotech Robotic Systems . Radiat Res . 2017 ; 187 : 492 ± 498 . https://doi.org/10.1667/RR011CC.1 PMID: 28231025
33. Scott RS , McMahon EJ , Pop SM , Reap EA , Caricchio R , Cohen PL , et al. Phagocytosis and clearance of apoptotic cells is mediated by MER . Nature . 2001 ; 411 : 207 ± 211 . https://doi.org/10.1038/35075603 PMID: 11346799
34. Wen Q , Hu Y , Zhang X , Kong P , Chen X . Gene expression signature of lymphocyte in acute lymphoblastic leukemia patients immediately after total body irradiation . Leuk Res . 2011 ; 35 : 1044 ± 1051 . https://doi.org/10.1016/j.leukres. 2010 . 12 .026 PMID: 21247631
35. Paul S , Barker CA , Turner HC , McLane A , Wolden SL , Amundson SA . Prediction of in vivo radiation dose status in radiotherapy patients using ex vivo and in vivo gene expression signatures . Radiat Res . 2011 ; 175 : 257 ± 265 . https://doi.org/10.1667/RR2420.1 PMID: 21388269
36. BrzoÂska K , Kruszewski M. Toward the development of transcriptional biodosimetry for the identification of irradiated individuals and assessment of absorbed radiation dose . Radiat Environ Biophys . 2015 ; 54 : 353 ± 363 . https://doi.org/10.1007/s00411-015 -0603-8 PMID: 25972268
37. Badie C , Dziwura S , Raffy C , Tsigani T , Alsbeih G , Moody J , et al. Aberrant CDKN1A transcriptional response associates with abnormal sensitivity to radiation treatment . Br J Cancer . 2008 ; 98 : 1845 ± 1851 . https://doi.org/10.1038/sj.bjc. 6604381 PMID: 18493234
38. Martin DR , Dutta P , Mahajan S , Varma S , Stevens SM . Structural and activity characterization of human PHPT1 after oxidative modification . Sci Rep . 2016 ; 6 : 23658 . https://doi.org/10.1038/srep23658 PMID: 27034094
39. O 'Brien G , Cruz-Garcia L , Majewski M , Grepl J , Abend M , Port M , et al. FDXR is a biomarker of radiation exposure in vivo . Sci Rep . 2018 ; 8 : 684 . https://doi.org/10.1038/s41598-017-19043-w PMID: 29330481
40. Zeegers D , Venkatesan S , Koh SW , Low GKM , Srivastava P , Sundaram N , et al. Biomarkers of Ionizing Radiation Exposure: A Multiparametric Approach . Genome Integr. 2017 ; 8: 6 . https://doi.org/10.4103/ 2041- 9414 .198911 PMID: 28250913